Synergistic Biomarkers for Early Colorectal Cancer Detection: 5-mC and 5-hmC
In this episode we speak with Robert Osborne, PhD, Senior Vice President of Research & Development at biomodal.
Robert will provide a high-level overview of biomodal’s bioRXiv preprint, 5 methylcytosine (5mC) and 5 hydroxymethylcytosine (5hmC) are synergistic biomarkers for early detection of colorectal cancer. During this interview, he will discuss the roles of 5 methylcytosine (5mC) and 5 hydroxymethylcytosine (5hmC) as biomarkers for early-stage colorectal cancer (CRC) detection in cell-free DNA (cfDNA).
What can you expect to learn:
- The expanding potential of liquid biopsy for early cancer detection by distinguishing between 5mC and 5hmC to improve the sensitivity of liquid biopsy tests.
- Methylation states of enhancers in CRC cfDNA samples provide evidence that 5mC and 5hmC track cancer stage with greater precision.
- Together, the 5mC and 5hmC model shows an 85% sensitivity (at 95% specificity) for early-stage cancer detection.
- Early-stage detection, CRC 5hmC is shown to provide complementary information to that of 5mC
This ground breaking data is a paradigm shift for liquid biopsy and cancer research.
Further Reading:
- bioRXiv preprint: 5 methylcytosine and 5 hydroxymethylcytosine are synergistic biomarkers for early detection of colorectal cancer
- duet multiomics solution evoC